Unlike the billion-dollar pharmaceutical giants, biotech firms offer the potential for big payoffs. It’s not unusual for a small or mid-sized biotech stock to fluctuate 10%, 20%, 30% or more in a single day after announcing the approval or disapproval of one of its drugs. Biotechnology ETFs offer a way to share in the success of those companies that succeed and limit losses on those that fail.